Dasgupta Paramita, Cramb Susanna M, Kou Kou, Yu Xue Qin, Baade Peter D
Cancer Research Centre, Cancer Council Queensland, Brisbane, Queensland, Australia.
School of Public Health and Social Work, Queensland University of Technology, Brisbane, Queensland, Australia.
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1825-1831. doi: 10.1158/1055-9965.EPI-20-0299. Epub 2020 Jul 22.
This study quantifies the number of potentially "avoided"cancer deaths due to differences in 10-year relative survival between three time periods, reflecting temporal improvements in cancer diagnostic and/or treatment practices in Australia.
National population-based cohort of 2,307,565 Australians ages 15 to 89 years, diagnosed with a primary invasive cancer from 1985 to 2014 with mortality follow-up to December 31, 2015. Excess mortality rates and crude probabilities of cancer deaths were estimated using flexible parametric relative survival models. Crude probabilities were then used to calculate "avoided cancer deaths" (reduced number of cancer deaths within 10 years of diagnosis due to survival changes since 1985-1994) for all cancers and 13 leading cancer types.
For each cancer type, excess mortality (in the cancer cohort vs. the expected population mortality) was significantly lower for more recently diagnosed persons. For all cancers combined, the number of "avoided cancer deaths" (vs. 1985-1994) was 4,877 (1995-2004) and 11,385 (2005-2014) among males. Prostate (1995-2004: 2,144; 2005-2014: 5,099) and female breast cancer (1,127 and 2,048) had the highest number of such deaths, whereas <400 were avoided for pancreatic or lung cancers across each period.
Screening and early detection likely contributed to the high number of "avoided cancer deaths" for prostate and female breast cancer, whereas early detection remains difficult for lung and pancreatic cancers, highlighting the need for improved preventive and screening measures.
Absolute measures such as "avoided cancer deaths" can provide a more tangible estimate of the improvements in cancer survival than standard net survival measures.
本研究通过量化三个时间段内10年相对生存率的差异所导致的潜在“可避免”癌症死亡人数,反映澳大利亚癌症诊断和/或治疗实践的时间性改善情况。
基于全国人口的队列研究,纳入2307565名年龄在15至89岁之间、于1985年至2014年被诊断为原发性浸润性癌症且随访至2015年12月31日的澳大利亚人。使用灵活的参数相对生存模型估计超额死亡率和癌症死亡的粗概率。然后,粗概率用于计算所有癌症和13种主要癌症类型的“可避免癌症死亡人数”(由于自1985 - 1994年以来生存情况变化,诊断后10年内癌症死亡人数的减少)。
对于每种癌症类型,近期诊断的患者的超额死亡率(癌症队列与预期人群死亡率相比)显著更低。对于所有癌症综合来看,男性中“可避免癌症死亡人数”(与1985 - 1994年相比)在1995 - 2004年为4877例,在2005 - 2014年为11385例。前列腺癌(1995 - 2004年:2144例;2005 - 2014年:5099例)和女性乳腺癌(1127例和2048例)的此类死亡人数最多,而在每个时间段内胰腺癌或肺癌的可避免死亡人数均少于400例。
筛查和早期检测可能是前列腺癌和女性乳腺癌“可避免癌症死亡人数”较多的原因,而肺癌和胰腺癌的早期检测仍然困难,这凸显了改进预防和筛查措施的必要性。
诸如“可避免癌症死亡人数”等绝对指标比标准净生存指标能更切实地评估癌症生存情况的改善。